NeOnc Technologies Holdings is trading at $5.01 (+7.27%), though the immediate catalyst is unclear.
- No clear August 24, 2026 company-specific announcement has been identified.
- Recent momentum follows positive Phase 2a NEO100 glioma results, including 48.9% six-month progression-free survival versus a 20% historical benchmark, announced on August 12, 2026; this does not directly explain the current session’s gain.
- Broader market indicators are mixed-to-lower.